In this article, I would like to give my personal assessment and opinion of some established pharmaceutical companies.

As a naive and uninformed person, I always believed that the pharmaceutical sector would play a major role in the future.

Now I have taken a closer look at the companies on the basis of fundamental key figures and have come to a very sobering conclusion.

However, I only evaluate the past and draw conclusions for the future from the past. I cannot evaluate and assess something like a pipeline because I lack the understanding and specialist knowledge.

-----------------------------------------------------------------------------------------------------------

I looked at the following companies:

Bayer $BAYN (-6.12%)

Eli Lilly $LLY (-7.56%)

Johnson & Johnson $JNJ (-3.01%)

Novo Nordisk $NOVO B (-6.66%)

Roche $ROG (-5.6%)

Pfizer $PFE (-4.59%)

Merck $MRK (-4.87%)

-----------------------------------------------------------------------------------------------------------

Let's start with the most popular title:

$NOVO B (-6.66%)

Novo Nordisk has the best fundamentals of all the stocks we looked at. The growth is right, the margins have been consistently above 30% since 2013 (unique selling point) and the return on equity is very high.

However, there has been disproportionately strong sales growth in the last 3 years. Probably due to GLP-1?

The question here is whether this growth can be maintained and whether sales can remain at this level? These uncertainties, as well as the regularization of GLP-1, could partly explain the fall in the share price in recent months. The valuation ratios are still quite sporty, but could this be justified in view of growth and margins? The quarterly figures will be very interesting.

I will start a savings plan and continue to monitor the shares.

-----------------------------------------------------------------------------------------------------------

$BAYN (-6.12%)

Bayer AG has lost over 60% of its share price since the beginning of 2023. In my naivety, I thought that the share was now attractively valued. In fact, it has a price/sales ratio of just 0.47% and yet I would not invest.

If you look at the balance sheets of the last 10 years and further back, growth and profitability, you can see that the share has always been fundamentally weak. At best, it may be interesting for a trade, but I would not invest.

---------------------------------------------------------------------------------------------------------

$LLY (-7.56%)

Eli Lilly is basically a good company with solid figures. However, there have been one or two ups and downs over the years and balance sheets. If the company had invested in 2017 despite the poor figures at the time, it would be up several hundred percent today.

2024 was a record year for Eli Lilly with a 32 % increase in sales to around USD 45 billion. The main reason for this growth was the strong sales figures for diabetes drugs and weight loss injections.

In my opinion, the share is heavily overvalued despite its qualities and lags behind Novo Nordisk in many respects (fundamentally). I expect a significant correction here. This may not occur until 2026 or 27, but a price/earnings ratio of over 70 is in no way justified.

-----------------------------------------------------------------------------------------------------------

$JNJ (-3.01%)

I think Johnson & Johnson is a conglomerate, as it also sells consumer goods. It has little to no growth, quite good profitability and a dividend of over 3%🤑.

I guess you don't necessarily have to own this share, as it doesn't stand out from the others in any way (but it does, it beats Bayer, for example, across the board) but it could possibly be a defensive stock for stability, if you value that sort of thing, and the dividend could also be a decisive factor if you buy it at the right time.

-----------------------------------------------------------------------------------------------------------

$PFE (-4.59%)

Pfizer is clearly a corona profiteer that achieved record sales in 2021 and 22. After Corona, the awakening and a share price drop of over 50 %.

From 2010-2020, sales even declined and margins ranged from 12% to over 40%. I suspect that the turn around to the pre-corona level could succeed, so my price target is $29-44.

Here, too, I do not see a quality company, not a must-have and at best a trade or the dividend, which is currently over 6%, could also be interesting here.

-----------------------------------------------------------------------------------------------------------

$ROG (-5.6%)

I thought only gold and chocolate came from Switzerland. That's not the case, because there is also Roche, not Ferrero Rocher but the pharmaceutical company. You would have to read up on this and find out more, because there seem to have been serious capital measures since 2022, which make the fundamental data look very negative.

So it looks (if the data from my data provider is correct) that Roche has not been profitable since 22. Operating profit in 2024 has fallen to a level similar to the lows of 2015 and 17. Cash flow and return on capital are negative and there has actually been no sales growth since 2019.

If you look at the company from 2011-2021, they were actually quite solidly positioned.

I don't want to make a clear judgment on Roche because I don't think I have enough information to be able to correctly interpret these figures for the last three years, because what looks like a pile of 💩 (chocolate) could also be an opportunity. But I don't know.

Incidentally, it looks very similar at Novartis $NOVN (-5.35%) looks very similar and so I am encouraged that there may be a political geographic background that needs to be identified in order to value these stocks correctly.

-----------------------------------------------------------------------------------------------------------

$MRK (-4.87%)

Merck shares are in the midfield. From 2010-2018, the figures even declined. Continuous growth has been observed since 2018, with record sales in the last 3 years in particular.

The share appears to be relatively cheaply valued with a P/E ratio of less than 14.

For me, the question remains whether this profitability is sustainable and whether a strong year will not be followed by another weak one. Personally, the risk/return ratio for Merck would be too low for me.

-----------------------------------------------------------------------------------------------------------

My conclusion:

I will keep my distance from the pharmaceutical sector, as I am not in a position to assess a pipeline and there could always be medical breakthroughs that I am unable to predict.

On the other hand, expected successes can also fail to materialize or lead to failures and economic losses due to official regulations.

In addition, research is very time and capital intensive and there is no guarantee of success.

I will be satisfied with the share of the pharmaceutical sector in my broadly diversified ETF and, contrary to the above conclusion, start a savings plan on Novo Nordisk 🤓

-----------------------------------------------------------------------------------------------------------

Thanks for reading and I welcome additions, corrections and opinions, but please don't be so hard on me. 😇

The markets remain volatile and in times of crisis many investors look for stable investments. But which sectors and companies have historically proven to be particularly resilient or could even benefit?

Consumer staples - products that will always be needed

Companies such as Procter & Gamble $PG (-4.13%) Nestlé $NESN (-3.88%) or Coca-Cola $KO (-3.58%) benefit from their strong market position and stable cash flows. People are always buying household products, food and beverages.

Healthcare sector - crisis-resistant growth stocks

Companies such as Johnson & Johnson $JNJ (-3.01%) , Eli Lilly $LLY (-7.56%) or Novo Nordisk $NOVO B (-6.66%) supply medicines and treatments that are in demand regardless of the economic situation. There is a particular focus on the boom in diabetes and obesity therapies.

Providers - Stable income through basic care

Companies such as NextEra Energy $NEE (-5.91%) Duke Energy $DUK (-3.24%) or Southern Company $SO (-3.12%) are benefiting from the constant demand for electricity and water. Renewable energies are also playing an increasingly important role.

Commodities & gold - hedging against inflation & uncertainty

Gold mining companies such as Barrick Gold $ABX (-8.2%) or Newmont $NEM (-7.84%) often benefit in times of economic uncertainty, as investors flee to gold as protection against crises.

Defense & Armaments - Profiteers of geopolitical tensions

Rising military spending worldwide makes companies such as Lockheed Martin $LMT (-3.69%) or Northrop Grumman $NOC (-5.33%) into potential winners of long-term conflicts and global uncertainties.

This is just a small selection of companies. But hopefully it gives a small insight into the interesting crisis-proof sectors.

Defensive investors could now focus on consumer staples, healthcare and utilities for long-term stability. Opportunity-oriented investors could look to commodities, gold or defense if geopolitical tensions continue to rise.

#stockanalysis
#dividends
#growth#inspiration

2025 - A stock market year that has so far been more reminiscent of rough seas. It goes uphill and the next moment it goes abruptly downhill again.

The January began with a lot of Trump euphoria on the markets, before this was halted by DeepSeek in the second half of January.

The February recovered relatively quickly from this shock before falling again in the second half of the month. The Trump euphoria has turned into a Trump shock for the time being.

Nevertheless, I will continue to hold a 75-80% USA quota with a high proportion of tea.

I can get over the fact that after 2 years of outperformance against my benchmarks, there may be an underperformance this year.

Monthly view:

In total, February was -3,2%. This corresponds to price losses of almost 10.000€.

The MSCI World (benchmark) was down -2.5% and the S&P500 -1.4%.

Winners & losers:

A look at the winners and losers nevertheless reveals a surprising picture for the top performer in February.

But first a look at the losersThe biggest loser by far is Alphabet $GOOG (-2.49%) With losses of almost €3,000, the share price took a heavy hit in February. This is followed by a total of almost €5,000 in price losses Bitcoin
$BTC (-0.15%) & Ethereum
$ETH (+0.07%) . 4th & 5th place goes to Salesforce
$CRM (-5.08%) and TSMC $TSM (-6.15%) two more tech stocks

On the winning side are actually at the top, much to my own surprise NVIDIA
$NVDA (-7.25%) with a price gain of almost €1,000. And this despite the fact that NVIDIA lost over 10% on the penultimate trading day in February. Nevertheless, the recovery after the DeepSeek shock in February was greater than expected.

The top 5 includes Amgen
$AMGN (-4.41%) and Johnson & Johnson
$JNJ (-3.01%) two stocks from the healthcare sector, a rather defensive sector. These are joined by MercadoLibre $MELI (-4.71%) and Palo Alto Networks $PANW (-6.21%) but also two tech stocks.

The performance-neutral movements were positive again in February at € 900, after January was clearly negative due to a property purchase.

current year:

In the YTD my portfolio is still just in the plus with +0,6%. However, the MSCI World is up +1.9% and I am currently underperforming my benchmark.

In total, my portfolio currently stands at ~288.000€. This corresponds to an absolute growth of ~€3,000 in the current year 2025. ~1.000€ of this comes from price increases, ~500€ from dividends / interest and ~1.500€ from additional investments.

Dividend:

• Dividends in February were 19% above the previous year at ~€188
• At the top of the list Procter & Gamble
  $PG (-4.13%) with now over €50 (gross) dividend every 3 months
• In the current year, the dividends after 2 months are +24% over the first 2 months of 2025 at ~350€

Buys & sells:

• I bought in November for ~800€
• 520€ shares
• 210€ ETFs
• Here I took up a new ETF via a savings plan, an ETF that normally does not correspond to my strategy at all. This is a Covered Call ETF on the NASDAQ $JEPQ (-4.98%) - The ETF uses a covered call strategy to aim for a distribution of ~10% p.a. and still generate price gains. I know that this doesn't make sense from a tax perspective, but what the heck: you can have fun sometimes 😉
• 100€ crypto
• sales there were none in February

YouTube:

I uploaded a few new videos to YouTube in February and I'm starting to feel less stupid talking into a microphone.

I've also uploaded my portfolio update there as a video if anyone would like to see some more information about the portfolio performance in February:

https://youtu.be/iJZ0i3EO5Hs

Here I act according to the motto: Let's see what happens - What will happen!

Goal 2025

Building a house makes it particularly difficult to formulate a goal this year.

A certain savings rate? Difficult if additional costs are suddenly added

A certain deposit value? Also difficult, as I can't really back this up with my savings rate this year and the markets are very volatile.

The current portfolio balance is ~€290,000. I would estimate additional investments at ~€15,000. This would bring me to just over €300,000. I originally assumed a market return of 7% for this year. However, after the first two months it is difficult for me to estimate how this year will go.

That's why I'm being honest: A target doesn't make sense for me this year.

The goal is to build a successful house and for the portfolio we'll just see what happens.

#dividends

#dividende

#rückblick

#depotupdate

#aktie

#stocks

#etfs

#crypto

#personalstrategy

Share analysis Johnson & Johnson 💊🏥🇺🇸 $JNJ (-3.01%)

- Company portrait

- Business model

- Operating business

- Performance

- Business strategy

- Management

- Quarterly figures

Link: https://www.ideas-magazin.de/2025/ausgabe-275/maerkte/johnson-johnson-stabilitaet-und-wachstum/?utm_source=techaktien-instagram&utm_medium=influencer&utm_content=aktie&utm_campaign=ideas-magazin

#johnsonjohnson
#johnsonandjohnson
#aktien
#analyse

Closed position as planned with approx. 10% profit. Had bought a small tranche in the meantime.

What are your favorites that you will keep for the next few years?

or do you have several 🤔

I only have Johnson and Johnson

and Merck in another portfolio

Novo Nordisk$NOVO B (-6.66%)

J&J $JNJ (-3.01%)

merck&co $MRK (-4.87%)

and all the others that exist

In the current issue, "Der Aktionär" recommends these dividend stocks.

For a peaceful night's sleep (conservative):

• E.On $EOAN (-6.15%)
• Johnson & Johnson $JNJ (-3.01%)
• Munich Re $MUV2 (-6.68%)
• PepsiCo $PEP (-1.81%)
• Procter & Gamble $PG (-4.13%)

Top dividend with medium risk can be seen in:

• Andritz $ANDR (-5.65%)
• Freenet $FNTN (-5.99%)
• Imperial Brands $IMB (-3.63%)
• Traton $8TRA (-8.68%)

Dividends with a yield kick are located in these shares:

• Frontline $FRO (-9.63%)
• Petrobas $PETR3 (-7.38%)
• Repsol $REP (-5.51%)
• Stellantis $STLAM (-4.48%)

Source: Der Aktionär, Issue 08.2025

Dear friends of Getquin,

I'm usually a silent reader, but if everyone just reads, eventually there's no more reading material, is there? So today I want to share my story with you.

The beginnings:

It's hard for me to say exactly when my journey began, but I do know that I developed a fascination with money as a child. My first "investment" was when I was about 7 or 8 years old, when I bought an ounce of gold with my own pocket money. At that time, no one in my family had anything to do with investments, but I had seen it in my mother's bank when I often accompanied her there. I was fascinated by the shiny coins and wanted to know how I could have a piece myself.

Then, around the turn of the millennium, I saw my father, together with a "great" bank advisor, invest the entire family savings in the middle of the dotcom bubble. The result: a massive loss within a few months. But my mother, who was at home at the time, fought hard and was miraculously able to recoup the losses. I was about 9 or 10 years old at the time and watched her sit in front of the PC every day and look at the figures. From that moment on, I was hooked! I started using an Excel spreadsheet to track which shares I would have bought at what price and watched the performance of my fictitious investments with great interest every day after school.

The first few years:

My mother stopped day trading after about a year and went back to work. However, shares were no longer an issue for me until I was 26.

Getting into real shares:

In 2018, in the summer, as a die-hard Juventus fan, I read about an article on the transfer of CR7 and how Juventus shares went through the roof. I was there again! At that time, however, I only had a small income as a working student. My father, who had failed with his investments in the past, gave me €2,000 - and I bought Juventus shares. However, he made me promise him that I would never invest in shares again. How did the story end? The "trade" with Juventus was a success, but I had to pay taxes for the first time - and I still hate that to this day.

The first losses:

After my Juventus adventure, I began to delve deeper into the matter. I tried out recommendations from "Aktionär" and repeatedly bet on individual shares for smaller trades. It was more of a game, but I generally remained profitable - sometimes a few percent profit, sometimes a few percent loss. Thanks to the profits and additional deposits, I built up my portfolio to €18,000 until I was hit by Wirecard. In the end, I had to accept a loss of around €6,000. It was painful, but not life-threatening - and I learned a lot from this mistake. In particular, I made the mistake of constantly buying more. If I had left it at the original position of € 1,500, the loss would probably not have been so dramatic.

Don't give up:

After the Wirecard debacle, I radically rethought my strategy. I increasingly focused on conservative companies, regular dividend payers and low growth. But here, too, I realized that I was underperforming the market. So I adapted my strategy further and took a long-term approach. I have since been able to slowly recoup my losses.

The clean cut - a new start:

In the summer of 2023, I needed all my assets for a private housing project and decided to make a real "fresh start". I sold all the positions in my portfolio and only kept my ETF savings plans with TradeRepublic.

The new era:

When the housing project was completed, I wanted to build up a new portfolio with the money I had left over - and here you can see the result. My aim is to find companies that are growing strongly and have a solid moat. Dividends are nice, but not a must. My portfolio also contains defensive, boring stocks as a healthy addition. At the same time, I try to further expand my ETF positions through one-off purchases - I stopped my regular ETF savings plans at the end of January 2025. I have also invested a little in crypto and gold on the side. I have made further investments in Lego (€500), Pokémon (€1,000) and Counterstrike cases (€3,000), but these are not part of the public list - that would be too costly for me.

Fun fact:

My cash ratio has never been higher than €3,000 since I first entered the stock market (2018). This is currently an exception because I want to build up a cash reserve for the next generation.

Goal:

I don't have a specific, set goal when it comes to my investments. It's more of a hobby for me. I just enjoy seeing how my portfolio grows and how I can accompany exciting companies and be a small part of them as they develop. For me, it feels a bit like collecting: I enjoy discovering interesting companies, investing in them and watching them develop over the long term.

Thank you:

A big thank you goes to Goldesel Investing and Markus Koch, who have been with me since my first stock market steps. Without you, the share culture in German-speaking countries would certainly not be as strong! And of course a big thank you to Getquin - I've always dreamed of a platform like this! 0% bullshit, 100% investments.

I hope you like the revised version! The text is now more clearly structured, reads more smoothly and still retains your personal style.

Please let me know if you liked my story!

A little tip: My Bitpanda portfolio has a longer history, but I was too lazy to enter everything manually. I also didn't want to take over the history because, as I said, I wanted to start a new chapter in my investment history in November 2023. Overall, however, my crypto track is up €3000-4000.

$CSPX (-5.42%)
$ETH (+0.07%)
$BLK (-7.33%)
$GS (-7.35%)
$XDWD (-5.67%)
$V (-6.9%)
$MC (-4.14%)
$MS (-7.32%)
$QCOM (-7.67%)
$JNJ (-3.01%)
$ASML (-2.09%)
$RBOT (-5.7%)
$LOCK (-5.17%)
$MRK (-4.87%)
$UNP (-3.99%)
$NKE (+3.05%)
$QDV5 (-3.45%)
$MA (-7.72%)
$TGT (+1.89%)
$PEP (-1.81%)
$NU (-6.44%)
$AAPL (-6.8%)
$TSLA (-9.97%)
$DOGE (+0.29%)
$BTC (-0.15%)
$BRK.B (-6.3%)
$PEPE (+0.84%)

Hello, I am thinking about restructuring my portfolio, which in my opinion is very unbalanced, with a view to the future. I'm thinking of an investment horizon of around 15-20 years.

I would like to structure the core of my portfolio with the help of 60% #etfs with the help of

• $VWRL (-4.62%) 30%
• $CSPX (-5.42%) 30%

In addition, around 5% of my postage portfolio is to be #crypto above all $BTC (-0.15%) consist of

I invest the remaining 35% in individual stocks.

• Technology sector 8%
• Thought of $MSFT (-2.36%) , $GOOGL (-2.74%) , $AMZN (-3.47%) , $SAP (-5.31%) ,$NVDA (-7.25%) in approximately equal parts
• Healthcare sector 4%
• Something like $JNJ (-3.01%) , $NOVN (-5.35%) , $NOVO B (-6.66%) but I'm not quite sure here yet, I want to read up on it in more detail
• Consumer sector 6%
• Thought of $COKE (-5.18%) , $1810 (-8.17%)
  $PG (-4.13%) but not sure yet either
• Industrial sector 5%
• Something like $6501 (-6.67%)
  $SIE (-7.45%)
• 
  Energy sector 7%
• $SHEL (-7.19%) , $ENR (-9.65%)
• 
  Financial sector
• $ALV (-8.43%) and $NU (-6.44%)

I currently have a monthly savings rate of 400-500 euros in addition to my studies and would divide this up accordingly and put it into a #sparplan and put it into a savings account.

What do you think of the weighting and do you have any tips, especially in the health sector?

Brief feedback is very welcome

#stockanalysis
#portfolio